PD-L1 Biomarker for Immunotherapy
To qualify for Tecentriq®-based immunotherapy, the cancer must test positive for the PD-L1 protein. Learn what researchers have found about PD-L1 and other biomarkers to identify patients suited for immunotherapy.
SEARCH OUR SITE
for past articles or specific information.